Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study


Por: Butzkueven, H, Farr, P, Ozakbas, S, Boz, C, Kalincik, T, Taylor, L, Van Der Walt, A, Alroughani, R, Buzzard, K, Skibina, O, Lechner-Scott, J, Laureys, G, Terzi, M, Van Pesch, V, Grand-Maison, F, Barnett, M, Kermode, A, Menoyo, JLS, Rojas, J, Willekens, B, Foschi, M, Ramo-Tello, C, Skromne, E, Dirks, P, Muros-Le Rouzic, E and Spelman, T

Publicada: 1 feb 2026 Ahead of Print: 1 dic 2025
Resumen:
Introduction: The MSOCR-R study evaluates the long-term effectiveness of ocrelizumab (OCR) in patients with relapsing multiple sclerosis (RMS) in real-world clinical settings. Methods: MSOCR-R is an ongoing, prospective, longitudinal, observational cohort study of people with RMS newly treated with OCR, using data from the international MSBase registry. The study started in July 2018, and data collected up to October 2023 were analyzed. Outcomes were confirmed disability worsening (CDW), progression independent of relapses (PIRA), and no evidence of disease activity (NEDA-3: absence of relapse, 24-week CDW, or imaging activity). Results: Overall, 1011 patients were enrolled (18.1% initiated OCR first-line therapy; 81.9% switched from previous treatment), with a median time of 3.4 years on OCR treatment. About 67% of patients were females. At OCR initiation, mean age was 41.9 years, median disease duration was 10.4 years, and median Expanded Disability Status Scale score was 3.0. The 4-year Kaplan-Meier probabilities of 24-week CDW or PIRA were 25.2% (95% CI 21.6-29.1) and 21.9% (95% CI 18.3-25.2), respectively. Annualized relapse rate substantially decreased from 0.58 (95% CI 0.53-0.63) before OCR to 0.05 (95% CI 0.04-0.06) after treatment initiation. NEDA-3 was assessed in 366 patients and the probability of achieving NEDA-3 was 39.7% (95% CI 36.0-43.5) at 4 years. Persistence on OCR was 88.0% (95% CI, 85.2-90.3) at 4 years. Better clinical outcomes were consistently observed among the first-line treatment cohort. Conclusion: The MSOCR-R study provides strong real-world evidence of OCR effectiveness in people with RMS.

Filiaciones:
Butzkueven, H:
 Monash Univ, Sch Translat Med, Dept Neurosci, Melbourne, Australia

 Alfred Ctr, MSBase Fdn, Melbourne, Australia

Farr, P:
 Alfred Ctr, MSBase Fdn, Melbourne, Australia

Ozakbas, S:
 Izmir Univ Econ, Med Point Hosp, Izmir, Turkiye

Boz, C:
 Karadeniz Tech Univ, Med Fac, Dept Neurol, Trabzon, Turkiye

Kalincik, T:
 Univ Melbourne, Dept Med, CORE, Melbourne, Australia

 Royal Melbourne Hosp, Neuroimmunol Ctr, Melbourne, Australia

Taylor, L:
 Univ Melbourne, Dept Med, CORE, Melbourne, Australia

Van Der Walt, A:
 Monash Univ, Sch Translat Med, Dept Neurosci, Melbourne, Australia

 Alfred Ctr, MSBase Fdn, Melbourne, Australia

Alroughani, R:
 Amiri Hosp, Qurtoba, Sharq, Kuwait

Buzzard, K:
 Monash Univ, Box Hill Hosp, Eastern Hlth Clin Sch, Dept Neurosci, Box Hill, Australia

Skibina, O:
 Monash Univ, Box Hill Hosp, Eastern Hlth Clin Sch, Dept Neurosci, Box Hill, Australia

Lechner-Scott, J:
 Univ Newcastle, Newcastle, Australia

Laureys, G:
 Ghent Univ Hosp, Ghent, Belgium

Terzi, M:
 Ondokuz Mayis Univ, Med Fac, Dept Neurol, Samsun, Turkiye

Van Pesch, V:
 Catholic Univ Louvain, Clin Univ St Luc, Brussels, Belgium

Grand-Maison, F:
 Neuro Rive Sud, Greenfield Pk, PQ, Canada

Barnett, M:
 Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

Kermode, A:
 Univ Western Australia, Nedlands, Australia

Menoyo, JLS:
 Hosp Galdakao Usansolo, Galdakao, Spain

Rojas, J:
 Hosp Univ CEM, Buenos Aires, Argentina

Willekens, B:
 Antwerp Univ Hosp, Edegem, Belgium

Foschi, M:
 AUSL Romagna, S Maria Croci Hosp, Dept Neurosci, MS Ctr,Neurol Unit, Ravenna, Italy

:
 Hosp Badalona Germans Trias & Pujol, Badalona, Spain

Skromne, E:
 Hosp Angeles Lomas, Inst Mexicano Neurociencias, Valle De Las Palmas, Mexico

Dirks, P:
 F Hoffmann La Roche Ltd, Basel, Switzerland

Muros-Le Rouzic, E:
 F Hoffmann La Roche Ltd, Basel, Switzerland

Spelman, T:
 Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
ISSN: 22110348





Multiple Sclerosis and Related Disorders
Editorial
Elsevier, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Estados Unidos America
Tipo de documento: Article
Volumen: 106 Número:
Páginas: 106885-106885
WOS Id: 001649432800001
ID de PubMed: 41421009
imagen Green Published, hybrid

MÉTRICAS